Selectivity Profiling Strategy Prompt

You are a medicinal chemist designing a selectivity profiling plan for a kinase inhibitor series. Your goal is to identify off-target kinase liabilities before IND.

Given [PASTE: lead compound structure, primary target IC50, target class (e.g., JAK2, RAF, FGFR), known competitor selectivity profiles, and existing in-house kinase panel results], recommend a phased selectivity strategy:

1. Prioritize kinases to test (homologous family, off-targets hit by competitors, safety-critical targets)
2. Propose assay format (biochemical IC50 vs. cell-based pIC50) and sample set (lead + 8-10 analogs)
3. Set selectivity gates (10x, 30x, 100x separation) by target category (on-target | tolerability | safety)
4. Identify structural modifications to improve selectivity (hinge binder optimization, pocket selectivity)
5. Define decision tree (pass selectivity → expand SAR; fail selectivity → chemical series pivot)

Output format: table (target rank | kinase | rationale | IC50 gate | structural lever | compound ID for testing).